Archived Content

 

Day 1  |  Day 2Download Agenda 

RNAi Brochure 

Download Agenda 


RNA interference (RNAi) is being commonly used as a screening tool for identifying and validating potential drug targets, exploring unknown cellular pathways, and for performing whole-genome functional screens. The screens developed, using both small interfering RNA (siRNA) and short hairpin RNA (shRNA), are now fairly robust and sensitive and can be performed in a reliable and high-throughput fashion. The RNAi for Functional Screening conference features talks on utilizing in vitro and in vivo RNAi screens for diverse applications, choosing the right model systems and reagents, tackling RNAi delivery, off-target effects, false positives and negatives and improving quality control and data analysis.

THURSDAY, NOVEMBER 3

 

Assay Design and Set-Up 

1:30 pm Chairperson’s Remarks

Christophe Echeverri, Ph.D., CEO & CSO, Cenix BioScience GmbH

1:40 Talk Title to be Announced

Alex Gaither, Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research

2:10 Screening Approaches Towards Identifying Genes Associated with DNA Re-Replication in Cancer Cells

Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, NIH

The NIH Chemical Genomics Center has established an RNAi screening facility that performs screens in collaboration with investigators throughout the NIH intramural community. An initial genome-wide campaign involved screening for genes associated with aberrant DNA replication. Screening was conducted using libraries comprised of both pooled and individual siRNAs. Combining these approaches led to a thorough examination of genes associated with DNA replication and served as a way to compare the value of both platforms.

2:40 RNAi Screening Comes of Age: For the Love of My Target

Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center

RNAi screening has offered the premise of performing several thousand simultaneous knockdowns leading to the discovery and validation of existing and novel targets. Several years on, has the technology matured enough to keep up with its premise?

3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 A Targeted Screen for Small Molecule Inhibitors of the Wnt/beta-catenin Pathway

Ramanuj DasGupta, Ph.D., Assistant Professor of Pharmacology and Director, RNAi Screening Facility, New York University School of Medicine/Cancer Institute


Sponsored by
Sigma_NEW 
4:15 A Library for microRNA Target Identification by Drug Selection
Kevin P. Forbes, Ph.D., Senior R&D Scientist, Sigma-Aldrich Corporation
To assist discovery and identification of human microRNA (miRNA) targets, we developed the MISSION® Target ID Library, a library of cDNA cloned after a dual-selection fusion protein. Dual-selection allows the user to transfect cells and screen the entire library at once, selecting first for stable transformants and secondly, downstream from introducing a miRNA of interest, for cDNAs containing the miRNA’s targets. Cells containing cDNA constructs targeted by the miRNA survive the second selection, and selected cDNAs can be identified by sequencing. The cDNA library was prepared from a mixture of total RNAs from multiple human tissues and cell lines to give broad coverage of the human transcriptome. Here we present preparation of the library and its use to identify targets of miR-373.

 

4:45 KEYNOTE PANEL: Has RNAi Screening Delivered On Its Promise?

Moderator: Christophe Echeverri, Ph.D., CEO/CSO, Cenix BioScience GmbH
Panelists: Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center
Caroline Shamu, Ph.D., Director, ICCB-Longwood Screening Facility, Harvard Medical School
Alex Gaither, Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research
Scott Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, NIH

Clive Geoffrey Jackson, Ph.D., Director, Biotech Evaluations Limited

5:45 End of Day

 

Day 1  |  Day 2Download Agenda 

DOT Hub Icon

2015 Discovery on Target Brochure  

2015 BROCHURE 


 PREMIER SPONSORS 

Cellecta 

Domainex

Molecular Sensing 

Rosa Drug Development Advisors

Sigma_NEW

 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


IPR_Micrombiome 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


 

September 21 

Next-Generation Histone Deacetylase Inhibitors Symposia 

Strategies for Rare Diseases Symposia 

September 22 

Developing CRISPR-Based Therapies Symposia 

September 22 - 23 

Targeting Epigenetic Readers and Chromatin Remodelers 

Targeting the Ubiquitin Proteasome System 

Targeting the Microbiome 

GPCR - Based Drug Discovery - Part 1 

Antibodies Against Membrane Protein Targets - Part 1 

RNAi for Functional Genomics Screening 

Gene Therapy Breakthroughs 

Targeting Ocular Disorders 

September 23 - 24 

Targeting Histone Methyltransferases and Demethylases 

Targeting the Unfolded Protein Response 

Kinase Inhibitor Discovery 

GPCR-Based Drug Discovery - Part 2 

Antibodies Against Membrane Protein Targets - Part 2 

New Frontiers in Gene Editing 

Quantitative Systems Pharmacology 

Short Courses 

SC1: Cancer Metabolism: Pathways, Targets and Clinical Updates 

SC2: Leveraging Data and Analytics for Drug DiSCovery 

SC3: Setting Up Effective Rnai SCreens: From Design to Data to Validation 

SC4: Phenotypic SCreening and Chemical Probe Development 

SC5: GPCR Structure-based Drug Discovery 

SC6: Targeting of GPCRs with Monoclonal Antibodies 

SC7: Setting Up Effective Functional SCreens Using 3D Cell Cultures 

SC8: Targeting Protein-protein Interactions: Biophysical Approaches 

SC9: Preclinical Animal Models for Ocular Indications 

SC10: Introduction to Allosteric Modulators and Biased Ligands of GPCRs 

SC11: Introduction to Targeted Covalent Inhibitors 

SC12: Assays and High-throughput SCreening for Novel Epigenetic Inhibitors 

SC13: Gamification and Drug Target Challenges 

SC14: A Primer to Gene Editing: Tools and Applications 

SC15: Using Mechanistic Physiological Models In Drug Development